Antibody

87개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved87 programs
AntibodyLimited DatastaleRochePhase 2

Recombinant Human Interleukin-2 and Rituximab (Recombinant Human Interleukin-2 and Rituximab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#monoclonal-antibody#Lymphoma+2
Trials 1Status Discontinued
AntibodyLimited DatastaleInnoventPhase 2

PD-1 inhibitor (Sintilimab, Sintilimab (PD-1 inhibitor))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LargeBCellDiffuseLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Siplizumab (Siplizumab)

T-Cell Peripheral Lymphoma; Gamma Delta Hepatosplenic T-Cell Lymphoma · T-Cell Peripheral Lymphoma

#T-CellPeripheralLymphoma#Antibody#Phase1#monoclonal-antibody#GammaDeltaHepatosplenicT-CellLym+1
Trials 1Status Active
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Tiselizumab (Tiselizumab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab at emerging CRS (Tocilizumab at emerging CRS)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Rituximab+1
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#monoclonal-antibody#High-gradeB-cellLymphoma+1
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 3

Tositumomab and Iodine I 131 Tositumomab (Tositumomab and Iodine I 131 Tositumomab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase3#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleCABYCPhase 2

Y-90 Ibritumomab tiuxetan (Y-90 Ibritumomab tiuxetan)

Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#monoclonal-antibody#CABYC
Trials 1Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Discontinued
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active
AntibodyLimited DatastaleSeoul National University Hospi…Phase 2

bendamustine plus rituximab (bendamustine plus rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Seoul
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#B-cellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleBeth ChristianPhase 2

milatuzumab (milatuzumab)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Beth
Trials 1Status Active

4 / 5 pages

← PreviousNext →